Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254147 | 0.81 | CRHR1 (0.48) | CRHR1MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL5252847 | 0.73 | CRHR1 (0.40) | CRHR1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5258073 | 0.71 | CRHR1 (0.49) | CRHR1MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL5254145 | 0.67 | — | — | |
| SCHEMBL512267 | 0.65 | LMNA (0.38) | — | |
| SCHEMBL5257621 | 0.64 | CRHR1 (0.48) | CRHR1MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL512499 | 0.62 | HRH3 (0.36) | CYP3A4 | |
| SCHEMBL3271338 | 0.61 | TP53 (0.38) | CRHR1ALDH1A1TSHR | |
| SCHEMBL512845 | 0.61 | HRH2 (0.33) | CYP3A4 | |
| SCHEMBL513642 | 0.60 | EEF2K (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | claimed |
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1656354-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005014557-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | CRHR1, AVPR2, CRHR2 | CRHR1 1/4885MEN1 438/4885KMT2A 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.